Therefore, it is tempting to anticipate that PPARβ/δ deficiency in MSC could affect their survival rate and reduce their engraftment once injected in vivo since PPARβ/δ has been described to promote survival of several cell types, including cancer cells and cardiomyocytes (47, 48) [for review see (49)]. Here, PPARD is linked to cancer.